Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

REMAP-CAP tocilizumab, 2021
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif
  • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
  • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
Veiga, 2021
 
NCT04403685
RCTtocilizumab controlCOVID-19 severe or criticallysome concern
65/64 safety concern
  • safety concern with 1.7-fold increase in deaths (not statistically significant)
BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID-19 severe or criticallylow
161/81 inconclusive
  • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
294/144 inconclusive
    Andrew, 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
    198/413 inconclusive
      Biran, 2020 OBStocilizumab controlCOVID-19 severe or criticallyserious
      210/420 suggested
      • suggested 36 % decrease in deaths but with a low degree of certainty due to high risk of bias
      Mathilde, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
      30/29 suggested
      • suggested 75 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
      Rojas-Marte, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
      96/97 inconclusive
        Somers, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
        78/76 safety concern
        • suggested 45 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
        • statistically significant 2.3-fold increase in superinfection but with a very low degree of certainty due to critical risk of bias
        TOCI-RAF Study Group (Campochiaro), 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
        32/33 inconclusive

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).